Related Experiment Video

Updated: Mar 25, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer

Ivana Sullivan1, David Planchard1

  • 1Medical Oncology Department, Gustave Roussy, 114 Rue Édouard Vaillant, 94805 Villejuif Cedex, France.

Future Oncology (London, England)
|February 20, 2016
PubMed

Insights

Next-generation ALK inhibitors like ceritinib and alectinib offer improved potency and efficacy for non-small-cell lung cancer (NSCLC) patients resistant to crizotinib. These advanced treatments show promise against resistant mutations and may improve central nervous system penetration.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic Lymphoma Kinase (ALK) gene rearrangements are crucial in non-small-cell lung cancer (NSCLC) pathogenesis.
  • ALK-positive NSCLC represents a significant subset of patients with oncogene addiction.
  • Crizotinib, a first-generation ALK inhibitor, is a standard treatment but faces acquired resistance.

Purpose of the Study:

  • To review the development and efficacy of next-generation ALK inhibitors.
  • To address the clinical need for agents effective after crizotinib resistance.
  • To highlight advancements in treating ALK-positive NSCLC.

Main Methods:

  • Literature review of clinical trials and preclinical studies.
  • Analysis of drug potency and activity against ALK mutations.
  • Evaluation of central nervous system penetration data.

Main Results:

  • Next-generation inhibitors (ceritinib, alectinib) demonstrate higher potency than crizotinib.
  • These agents are effective against tumors with crizotinib-resistant ALK mutations.
  • Improved central nervous system penetration is a potential benefit.

Conclusions:

  • Next-generation ALK inhibitors represent a vital advancement in NSCLC treatment.
  • Ceritinib and alectinib offer new therapeutic options for resistant disease.
  • Further research is warranted to optimize their use in clinical practice.
Keywords:
ALK-rearrangementCNS diseasealectinibceritinibcrizotinibcrizotinib-resistancenon-small-cell lung cancer

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K